Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321308 · ClinicalTrials.gov registry record · Phase 2
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00321308 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 36 participants.
The verdict
NCT00321308, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen
Interventions
- DRUG pemetrexed
- DRUG pemetrexed + PF-3512676
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321308
The ClinicalTrials.gov registry entry for NCT00321308 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.
NCT00321308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321308 about?
NCT00321308 is a clinical study titled "Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer". To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen
What is the current status of trial NCT00321308?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2006-09. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00321308?
The interventions under investigation include: pemetrexed (DRUG), pemetrexed + PF-3512676 (DRUG).
Who is sponsoring clinical trial NCT00321308?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.